source
- Biopharma Sentiment Index climbs to upbeat 105 in Q3 2026, marking strongest optimism in yearsEndpoints Signal released its Q3 2026 Biopharma Sentiment Index, showing a dramatic lift in industry mood. The survey indicates the sector is finally in a positive territory after a four-year downt…
- Rapport Therapeutics reports Phase 2 success for J&J-licensed bipolar mania drugRapport Therapeutics announced that its oral investigational drug, which modulates AMPA receptors, has successfully completed a Phase 2 trial in patients with bipolar mania. The study met its prim…